Education
About Us
Working with TipRanks
Follow Us
Y-Mabs Therapeutics (YMAB)
NASDAQ:YMAB
| Dec 24 | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 87.69M | $ 84.82M | $ 65.27M | $ 34.90M | $ 20.75M |
| Gross Profit | $ 72.43M | $ 73.40M | $ 57.70M | $ 32.38M | $ 18.55M |
| Operating Income | $ -31.20M | $ -25.67M | $ -94.81M | $ -115.43M | $ -119.94M |
| EBITDA | $ -31.20M | $ -24.94M | $ -94.73M | $ -54.49M | $ -119.54M |
| Net Income | $ -29.67M | $ -21.43M | $ -96.33M | $ -56.34M | $ -118.34M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 67.23M | $ 78.64M | $ 105.76M | $ 181.56M | $ 114.63M |
| Total Assets | $ 119.90M | $ 127.87M | $ 141.46M | $ 212.78M | $ 132.05M |
| Total Debt | $ 820.00K | $ 1.42M | $ 1.77M | $ 3.63M | $ 3.98M |
| Net Debt | $ -66.41M | $ -77.22M | $ -104.00M | $ -177.93M | $ -110.66M |
| Total Liabilities | $ 27.90M | $ 26.88M | $ 32.23M | $ 32.68M | $ 26.21M |
| Stockholders' Equity | $ 92.00M | $ 100.98M | $ 109.22M | $ 180.11M | $ 105.84M |
| Cash Flow | |||||
| Free Cash Flow | $ -15.71M | $ -27.23M | $ -75.92M | $ -103.52M | $ -91.41M |
| Operating Cash Flow | $ -15.71M | $ -27.23M | $ -75.92M | $ -102.56M | $ -91.23M |
| Investing Cash Flow | $ 0.00 | $ 0.00 | $ 0.00 | $ 61.04M | $ -2.79M |
| Financing Cash Flow | $ 4.31M | $ 100.00K | $ 84.00K | $ 108.31M | $ 2.00M |